Journal Scans
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
DL Jr Bushnell, TM O'Dorisio, MS O'Dorisio, Y Menda, RJ Hicks, E Van Cutsem, JL Baulieu, F Borson-Chazot, L Anthony, AB Benson, K Oberg, AB Grossman, M Connolly, H Bouterfa, Y Li, KA Kacena, N Lafrance, SA Pauwels
20100201
2010 Mar 1
J Clin Oncol
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
J Clin Oncol. 2010 Mar 1; Epub ahead of print, DL Jr Bushnell, TM O'Dorisio, MS O'Dorisio, Y Menda, RJ Hicks, E Van Cutsem, JL Baulieu, F Borson-Chazot, L Anthony, AB Benson, K Oberg, AB Grossman, M Connolly, H Bouterfa, Y Li, KA Kacena, N Lafrance, SA Pauwels
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Carcinoid tumors, which are neuroendocrine tumors of the gastrointestinal (GI) tract and bronchus, show low response rates to chemotherapy. Octreotide controls carcinoid symptoms such as diarrhea and flushing for a median of 13 months, but it has shown no effect on survival. 90Y-DOTA-tyr3-octreotide (90Y-edotreotide) binds with high affinity to somatostatin receptors; the yttrium-90 molecule it contains is a high-energy beta emitter. This compound may thus deliver a tumoricidal level of radiation...
